Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Pallavi Bedi (Edinburgh, Scotland, United Kingdom), Pallavi Bedi, James Chalmers, Pira Sarvanamuthu, Adriano Rossi, Adam Hill. Atorvastatin as novel treatment in bronchiectasis patients colonized with pseudomonas aeruginosa. Eur Respir J 2016; 48: Suppl. 60, 1556

Member's Comments

No comment yet.

Related content which might interest you: Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives Year: 2015 A comprehensive analysis of the impact of pseudomonas aeruginosa colonisation in adult bronchiectasis Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives Year: 2015 Patients with no cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa: Role of inhaled colistin Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014 Should pseudomonas aeruginosa be the main target in bronchiectasis? Source: International Congress 2016 – Monitoring comorbidities Year: 2016 Genotypic studies of pseudomonas aeruginosa isolates from adult non-cystic fibrosis bronchiectasis patients Source: International Congress 2015 – Advances from translational research in respiratory infections Year: 2015 Role of stenotrophomonas maltophilia infection in CF pulmonary exacerbations Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Pseudomonas aeruginosa isolates in bronchiectasis: Wath particulaties and risk factors? Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 COPD and pseudomonas aeruginosa, an association Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014 Nicotinamide and bacterial killing in patients with non-cystic fibrosis bronchiectasis Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Prolonged oral corticosteroid therapy in allergic bronchopulmonary aspergillosis (ABPA) treatment does not increase pseudomonas aeruginosa risk Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015 Effectiveness of inhaled colistin by iNeb® device in non-CF bronchiectasis and chronic pseudomonas infection Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015 Azithromycin in chronic respiratory infections with pseudomonas aeruginosa in patients without cystic fibrosis Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host Year: 2008 Aminoglycoside use for pseudomonas aeruginosa in bronchiectasis Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Acute exacerbations of COPD due to pseudomonas aeruginosa: Impact of antimicrobial resistance Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance Year: 2015 Pseudomonas aeruginosa colonisation in patients without bronchiectasis Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014 Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015 Targeting Antibiotics to Pseudomonas aeruginosa in Small airways (TAPAS) in patients with Cystic Fibrosis Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021 Severe exacerbations of chronic obstructive pulmonary disease (COPD) due to Pseudomonas aeruginosa: resistance to common antibiotics Source: Eur Respir J 2001; 18: Suppl. 33, 540s Year: 2001